Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.

Détails

ID Serval
serval:BIB_69A083574849
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
Périodique
European radiology
Auteur(s)
Gorodetski B., Chapiro J., Schernthaner R., Duran R., Lin M., Lee H., Lenis D., Stuart E.A., Nonyane B.A., Pekurovsky V., Tamrazi A., Gebauer B., Schlachter T., Pawlik T.M., Geschwind J.F.
ISSN
1432-1084 (Electronic)
ISSN-L
0938-7994
Statut éditorial
Publié
Date de publication
02/2017
Peer-reviewed
Oui
Volume
27
Numéro
2
Pages
526-535
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article
Publication Status: ppublish
Résumé
Our study sought to compare the overall survival in patients with hepatocellular carcinoma (HCC) and portal venous thrombosis (PVT), treated with either conventional trans-arterial chemoembolization (cTACE) or drug-eluting beads (DEB) TACE.
This retrospective analysis included a total of 133 patients, treated without cross-over and compared head-to-head by means or propensity score weighting. Mortality was compared using survival analysis upon propensity score weighting. Adverse events and liver toxicity grade ≥3 were recorded and reported for each TACE. In order to compare with historical sorafenib studies, a sub-group analysis was performed and included patients who fulfilled the SHARP inclusion criteria.
The median overall survival (MOS) of the entire cohort was 4.53 months (95 % CI, 3.63-6.03). MOS was similar across treatment arms, no significant difference between cTACE (N = 95) and DEB-TACE (N = 38) was observed (MOS of 5.0 vs. 3.33 months, respectively; p = 0.157). The most common adverse events after cTACE and DEB- TACE, respectively, were as follows: post-embolization syndrome [N = 57 (30.0 %) and N = 38 (61.3 %)], diarrhea [N = 3 (1.6 %) and N = 3 (4.8 %)], and encephalopathy [N = 11 (5.8 %) and N = 2 (3.2 %)].
Our retrospective study could not reveal a difference in toxicity and efficiency between cTACE and DEB-TACE for treatment of advanced stage HCC with PVT.
• Conventional TACE (cTACE) and drug-eluting-beads TACE (DEB-TACE) demonstrated equal safety profiles. • Survival rates after TACE are similar to patients treated with sorafenib. • Child-Pugh class and tumor burden are reliable predictors of survival.

Mots-clé
Aged, Antineoplastic Agents/administration & dosage, Carcinoma, Hepatocellular/complications, Carcinoma, Hepatocellular/therapy, Chemoembolization, Therapeutic/methods, Female, Humans, Liver Neoplasms/complications, Liver Neoplasms/therapy, Male, Middle Aged, Niacinamide/administration & dosage, Niacinamide/analogs & derivatives, Phenylurea Compounds/administration & dosage, Portal Vein, Retrospective Studies, Survival Analysis, Survival Rate, Treatment Outcome, Venous Thrombosis/complications
Pubmed
Création de la notice
13/06/2016 11:37
Dernière modification de la notice
20/08/2019 15:24
Données d'usage